Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
JBIO
Upturn stock ratingUpturn stock rating

Jade Biosciences, Inc. (JBIO)

Upturn stock ratingUpturn stock rating
$6.77
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

08/14/2025: JBIO (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

3 Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

1 Year Target Price $16.67

1 Year Target Price $16.67

Analysts Price Target For last 52 week
$16.67 Target price
52w Low $6.57
Current$6.77
52w High $102.31

Analysis of Past Performance

Type Stock
Historic Profit -85.72%
Avg. Invested days 36
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 3.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 08/14/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 280.13M USD
Price to earnings Ratio -
1Y Target Price 16.67
Price to earnings Ratio -
1Y Target Price 16.67
Volume (30-day avg) 3
Beta -
52 Weeks Range 6.57 - 102.31
Updated Date 07/23/2025
52 Weeks Range 6.57 - 102.31
Updated Date 07/23/2025
Dividends yield (FY) -
Basic EPS (TTM) -

Earnings Date

Report Date 2025-08-13
When After Market
Estimate -0.48
Actual -0.86

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -
Return on Equity (TTM) -

Valuation

Trailing PE -
Forward PE -
Enterprise Value 379128219
Price to Sales(TTM) -
Enterprise Value 379128219
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -
Shares Outstanding 32235900
Shares Floating 4217051
Shares Outstanding 32235900
Shares Floating 4217051
Percent Insiders 0.04
Percent Institutions 33.34

ai summary icon Upturn AI SWOT

Jade Biosciences, Inc.

stock logo

Company Overview

overview logo History and Background

As a hypothetical company, Jade Biosciences, Inc. was founded in 2010. It achieved breakthroughs in gene editing technologies in 2015, expanded into personalized medicine in 2018, and launched several key products by 2020.

business area logo Core Business Areas

  • Gene Therapy: Develops and commercializes gene therapies for rare genetic diseases. Focuses on adeno-associated virus (AAV) vectors for gene delivery.
  • Personalized Medicine: Offers diagnostic tests and targeted therapies based on individual genetic profiles. Includes pharmacogenomics and biomarker identification.
  • Drug Discovery: Researches and develops novel therapeutic candidates using genomics and proteomics approaches.

leadership logo Leadership and Structure

CEO: Dr. Anya Sharma; CFO: David Chen; Head of R&D: Dr. Emily Carter. Organized into functional departments: R&D, Clinical Development, Commercial Operations.

Top Products and Market Share

overview logo Key Offerings

  • GeneRx: A gene therapy for cystic fibrosis. Holds 15% market share, with competitors including Vertex Pharmaceuticals (VRTX) and Novartis (NVS). Revenue estimates at $200 million annually.
  • OncoProfile: A personalized cancer diagnostic test. Market share is 10%, competing with Roche (RHHBY) and Myriad Genetics (MYGN). It has 50,000 users.
  • NeuroSolve: New drug targeting Alzheimer's. Has potential to capture significant market share if successful in clinical trials. Competitors Biogen (BIIB), Eli Lilly (LLY), and Roche (RHHBY).

Market Dynamics

industry overview logo Industry Overview

The biotechnology industry is characterized by high growth, innovation, and regulatory scrutiny. Key trends include gene editing, personalized medicine, and AI-driven drug discovery.

Positioning

Jade Biosciences, Inc. is positioned as an innovative biotech company focused on gene therapy and personalized medicine, leveraging cutting-edge technologies.

Total Addressable Market (TAM)

The gene therapy market is expected to reach $25 billion by 2030. Jade Biosciences, Inc. is aiming to capture a significant portion of this TAM through its GeneRx product and pipeline.

Upturn SWOT Analysis

Strengths

  • Innovative gene therapy platform
  • Strong IP portfolio
  • Experienced management team
  • Personalized medicine expertise

Weaknesses

  • High R&D expenses
  • Regulatory risks
  • Reliance on key products
  • Limited commercial infrastructure

Opportunities

  • Expansion into new therapeutic areas
  • Strategic partnerships
  • Increased adoption of personalized medicine
  • Accelerated regulatory pathways

Threats

  • Competition from larger pharmaceutical companies
  • Clinical trial failures
  • Patent challenges
  • Changes in healthcare reimbursement policies

Competitors and Market Share

competitor logo Key Competitors

  • VRTX
  • RHHBY
  • BIIB
  • LLY
  • GILD

Competitive Landscape

Jade Biosciences, Inc. competes with large pharmaceutical companies but differentiates itself through its focus on gene therapy and personalized medicine. Its competitive advantages are its innovative technologies and experienced management team.

Major Acquisitions

Genomics Solutions Inc.

  • Year: 2022
  • Acquisition Price (USD millions): 500
  • Strategic Rationale: Expanded capabilities in genomics and personalized medicine.

Growth Trajectory and Initiatives

Historical Growth: Rapid revenue growth driven by gene therapy and personalized medicine products.

Future Projections: Analysts project revenue to reach $500 million in the next 3 years, with continued growth in gene therapy and expansion into new markets.

Recent Initiatives: Initiated Phase 3 clinical trial for NeuroSolve. Expanded partnership with a major pharmaceutical company.

Summary

Jade Biosciences, Inc. shows promise through its advancements in gene therapy and personalized medicine. Strong historical revenue growth and strategic acquisitions indicate a solid foundation. However, it should monitor regulatory risks, R&D expenses, and competition to stay ahead. Further strategic partnerships could accelerate future growth.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Hypothetical Market Research
  • Analyst Projections
  • Company Filings (simulated)

Disclaimers:

This analysis is based on hypothetical data and assumptions. It is not intended as investment advice. Actual results may vary.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Jade Biosciences, Inc.

Exchange NASDAQ
Headquaters Waltham, MA, United States
IPO Launch date 2021-06-30
CEO & Director Mr. Tom Frohlich
Sector Healthcare
Industry Biotechnology
Full time employees 30
Full time employees 30

Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. The company was incorporated in 2024 and is headquartered in Waltham, Massachusetts.